AdilShamoo, ElizabethWoeckner. (2007) Ethical Flaws in the TeGenero Trial. The American Journal of Bioethics 7 , 90-92 /Shamoo A, Woeckner E. Ethical flaws in the TeGenero trial. Am J Bioeth 2007;7:90-2.Adil Shamoo, Elizabeth Woeckner. (2007) Ethical Flaws in the TeGenero ...
They revealed that six men were taken to intensive care after taking part in a phase I trial on monoclonal antibody treatment aimed at curing chronic lymphocytic leukemia, multiple sclerosis and arthritis. Such event will have an impact on the public faith in clinical testing process....
The first trial of TeGenero's TGN1412 (a T cell agonist) in humans took place at Parexel's clinical pharmacology research unit at Northwick Park ... J Singh,A Thilagam - 《International Journal of Quantum Chemistry》 被引量: 53发表: 1986年 ...
The article reports on issues related to the results of phase 1 clinical trial of German biotech TeGenero AG’s monoclonal antibody designed to activate the immune system’s T cells at a clinical trials unit based at Northwick Park Hospital in Harrow, London, England. The ...
TeGenero felled by test fiasco.The article reports that TeGenero, the German firm whose monoclonal antibody drug TGN1412 was involved in a disastrous Phase I trial, has filed for bankruptcy.EBSCO_bspChemical & Engineering News
The article reports that German biotech firm TeGenero AG has filed for bankruptcy just four months after a catastrophic safety trial with its immunomodulatory drug candidate TGN1412 left six healthy volunteers fighting for their lives. TGN1412 was developed for the treatment of certain autoimmune ...
Money and distorted ethical judgment about research: ethical assessment of the TeGenero TGN1412 trial. Am J Bioeth 2007;7:76-81.Emanuel EJ, Miller FG. Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial. Am J Bioethics 2007;7:76-81.Emanuel...
Six men were admitted to intensive care after taking part of the trial. The drug, TGN1412, is a humanized Mab with specificity for the T-lymphocyte surface receptor CD28, a component in the human immune response.EBSCO_bspPharmaWatch: Cancer...
The article reports on the filing of bankruptcy by the TeGenero AG, a German biotech firm, after the safety trial of its TGN1412 drug to six healthy volunteers which left fighting for their lives in London, England. Due to the incidents, the company states that the drug may no longer ...
Using a minimum anticipated biological effect level (MABEL) approach, a much lower dose of TGN1412 would have been used in the first-in-human (FIH) trial. For predicting in vivo effects of a biological, knowledge of the antibody, its target, and the interaction between the two is needed,...